Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

Neoadjuvant Cemiplimab Shows Durable Survival in CSCC Final Analysis

Final analysis of phase II neoadjuvant cemiplimab in resectable cutaneous squamous cell carcinoma showed durable EFS, no late recurrences, and no new safety signals.

By Dr. Revathy Mohan V.R., MBBS · 6 days ago · 5 min read

Oncology·JCO

Darovasertib and Crizotinib Show Survival Signal in Metastatic Uveal Melanoma

First-line darovasertib plus crizotinib produced a 34.1% response rate and median overall survival of 21.1 months in metastatic…

6 days ago

Oncology·JCO

Pembrolizumab Fails to Improve EFS With SBRT in Early NSCLC

KEYNOTE-867 found no event-free survival benefit from adding pembrolizumab to SBRT in unresected stage I-II NSCLC, with more…

6 days ago

Oncology·JCO

Methylphenidate Eases Fatigue in Hematologic Cancer Trial

A crossover trial in hematologic cancer found methylphenidate improved fatigue more than placebo, with mostly mild toxicity but…

6 days ago

Oncology·JCO

Pancreatic Cancer Trial: Toripalimab Plus FOLFIRINOX Improves EFS

Toripalimab added to modified FOLFIRINOX improved event-free survival in borderline resectable and locally advanced pancreatic cancer without higher…

6 days ago

Oncology·JCO

PFAS Exposure Linked to Higher ER-Negative Breast Cancer Risk in Sister Study

A Sister Study analysis linked PFOA and PFOS exposure to higher ER-negative breast cancer risk, with meta-analysis support…

6 days ago

Oncology·Blood

Dasatinib in Pediatric CML Examines Long-Term Efficacy and Endocrine Effects

A pediatric CML abstract examines dasatinib’s long-term efficacy and endocrine effects in chronic phase, with attention to growth…

6 days ago

Oncology·Gut

Oesophagogastric Cancer Research Priorities Refined by UK and Ireland Patients

Patients and clinicians in the UK and Ireland ranked oesophagogastric cancer research priorities, reshaping funding targets across treatment,…

6 days ago

Oncology·Cancer Disc

Rezatapopt Combination Strategies in p53 Y220C-Mutant Cancer Models

AACR abstract title only; no methods, results, or endpoints were available in the scraped text to support a…

6 days ago

Oncology·Cancer Disc

KAT5 Emerges as a Dual-Function Target in Endometrial Cancer

AACR abstract positions KAT5 as a dual-action target in endometrial cancer, with direct tumor effects and immune-modulating potential.

6 days ago

Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.